Orforglipron Impurity 17

Orforglipron Impurity 17 is a high‑purity reference standard and advanced synthetic intermediate supplied by Cosperpharm for the development, manufacturing, and regulatory quality control of Orforglipron—an oral, small‑molecule, non‑peptide GLP‑1 receptor agonist being developed by Eli Lilly for the treatment of type 2 diabetes and obesity. This Orforglipron Impurity 17 occupies a uniquely dual role in the pharmaceutical development pipeline: on the one hand, it serves as a late‑stage intermediate in the convergent synthesis of the Orforglipron API; on the other, it functions as a critical analytical reference standard for impurity profiling, method validation, and quality control (QC) testing. At Cosperpharm, each batch of Orforglipron Impurity 17 is manufactured under stringent quality control protocols, with rigorous characterization data provided to ensure batch‑to‑batch reproducibility and full regulatory compliance. With its well‑defined stereochemistry, high purity, and comprehensive analytical documentation, Orforglipron Impurity 17 empowers researchers and manufacturers to accurately monitor reaction progress, identify process‑related impurities, and successfully navigate ANDA, DMF, and IND regulatory submissions.

Product Parameters

Why Cosperpharm?

Cosperpharm is a trusted supplier of high‑purity pharmaceutical intermediates and reference standards. With a GMP‑compliant production infrastructure and state‑of‑the‑art analytical capabilities—including HPLC, LC‑MS, GC‑MS, and NMR—we ensure that every batch of Orforglipron Impurity 17 meets rigorous quality specifications. We provide comprehensive documentation support including Certificate of Analysis (COA), HPLC chromatograms, mass spectrometry data, and stability studies to facilitate your regulatory filings. Our streamlined logistics, competitive pricing, and responsive technical support make Cosperpharm your reliable partner for Orforglipron Impurity 17 and a full range of related reference standards.

Frequently Asked Questions (FAQ)

Q1: What is Orforglipron Impurity 17 used for?

A: This compound serves a dual purpose: as a key synthetic intermediate in the manufacturing of Orforglipron API, and as an analytical reference standard for impurity profiling, HPLC method development, method validation (AMV), and quality control (QC) testing.

Q2: Can you supply larger quantities for commercial manufacturing?

A: Absolutely. Cosperpharm offers custom synthesis and bulk supply up to multi‑kilogram scales. We welcome inquiries for both R&D and commercial quantities with competitive pricing.

Applications

1.Orforglipron API manufacturing – serves as a late‑stage synthetic intermediate in the multi‑step production of this oral GLP‑1 receptor agonist for type 2 diabetes and obesity indications.

2.Analytical method development – employed as a reference standard for HPLC, UPLC, and LC‑MS method validation and impurity profiling.

3.Quality control (QC) testing – routine release and stability testing of Orforglipron API and finished drug product batches.

4.Forced degradation studies – used to identify, characterize, and quantify degradation products and impurities in Orforglipron formulations under ICH‑recommended stress conditions.

5.Regulatory submissions – ANDA, DMF, and IND filings requiring impurity reference standards with full characterization and traceability.

6.Process development and scale‑up – monitoring synthetic reaction progress, optimizing reaction yields, and tracking impurity formation during process scale‑up.

7.GLP‑1 receptor agonist research – as an intermediate for the discovery and development of novel oral, non‑peptide small‑molecule GLP‑1 receptor agonists for metabolic disorders.

Contact Us

Ready to purchase Orforglipron Impurity 17 or request a sample? Contact Cosperpharm today for a competitive quotation, product documentation, or a technical consultation with our expert team.